These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31432174)

  • 1. Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review).
    Shi F; Gao J; Zou J; Ying Y; Lin H
    Mol Med Rep; 2019 Oct; 20(4):2979-2989. PubMed ID: 31432174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification.
    Agarwal S; Loder S; Brownley C; Cholok D; Mangiavini L; Li J; Breuler C; Sung HH; Li S; Ranganathan K; Peterson J; Tompkins R; Herndon D; Xiao W; Jumlongras D; Olsen BR; Davis TA; Mishina Y; Schipani E; Levi B
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E338-47. PubMed ID: 26721400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
    Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
    Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification.
    Felix-Ilemhenbhio F; Pickering GAE; Kiss-Toth E; Wilkinson JM
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.
    Agarwal S; Loder SJ; Breuler C; Li J; Cholok D; Brownley C; Peterson J; Hsieh HH; Drake J; Ranganathan K; Niknafs YS; Xiao W; Li S; Kumar R; Tompkins R; Longaker MT; Davis TA; Yu PB; Mishina Y; Levi B
    Mol Ther; 2017 Aug; 25(8):1974-1987. PubMed ID: 28716575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypoxic microenvironment: a driving force for heterotopic ossification progression.
    Huang Y; Wang X; Lin H
    Cell Commun Signal; 2020 Feb; 18(1):20. PubMed ID: 32028956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterotopic Ossification Following Upper Extremity Injury.
    Agarwal S; Loder S; Levi B
    Hand Clin; 2017 May; 33(2):363-373. PubMed ID: 28363301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drosophila models of FOP provide mechanistic insight.
    Le V; Anderson E; Akiyama T; Wharton KA
    Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative nonsteroidal antiinflammatory drugs and the prevention of heterotopic ossification after cervical arthroplasty: analysis using CT and a minimum 2-year follow-up.
    Tu TH; Wu JC; Huang WC; Chang HK; Ko CC; Fay LY; Wu CL; Cheng H
    J Neurosurg Spine; 2015 May; 22(5):447-53. PubMed ID: 25723121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of heterotopic ossification-Molecular background and current treatment strategies.
    Łęgosz P; Drela K; Pulik Ł; Sarzyńska S; Małdyk P
    Clin Exp Pharmacol Physiol; 2018 Dec; 45(12):1229-1235. PubMed ID: 30144316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical Excision of Heterotopic Ossification Leads to Re-Emergence of Mesenchymal Stem Cell Populations Responsible for Recurrence.
    Agarwal S; Loder S; Cholok D; Li J; Breuler C; Drake J; Brownley C; Peterson J; Li S; Levi B
    Stem Cells Transl Med; 2017 Mar; 6(3):799-806. PubMed ID: 28297577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints.
    Agarwal S; Loder SJ; Brownley C; Eboda O; Peterson JR; Hayano S; Wu B; Zhao B; Kaartinen V; Wong VC; Mishina Y; Levi B
    Dev Biol; 2015 Apr; 400(2):202-9. PubMed ID: 25722188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
    Luo Y; Alsamarah A; Zhang K; Hao J
    Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.